GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

GSK plc GSK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a ...

GSK (NYSE:GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Blenrep as a late-line option and as part ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory ...